How to Get Dayvigo (Lemborexant) in Georgia

What Dayvigo Is and Why Access Matters in Georgia

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for treating insomnia in adults who have difficulty falling asleep or staying asleep. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking wake-promoting orexin neuropeptides rather than broadly depressing the central nervous system.

Georgia has roughly 10.9 million residents, and an estimated 30% of U.S. adults report short sleep duration according to CDC surveillance data. Access to newer insomnia medications matters because many patients fail first-line behavioral therapy or experience residual symptoms on older drugs. The SUNRISE-1 trial (N=1,006), published in JAMA Network Open, demonstrated that lemborexant 5 mg and 10 mg significantly improved objective sleep onset latency and wake-after-sleep-onset compared with placebo and the comparator zolpidem extended-release 6.25 mg at 30 nights of treatment. Sleep onset latency decreased by 10.5 minutes with lemborexant 10 mg versus 3.2 minutes with placebo (P<0.001) [1].

Georgia's regulatory environment supports controlled-substance telehealth prescribing, which opens a practical pathway for patients in rural counties who may live hours from a sleep specialist.

Telehealth Prescribing of Dayvigo in Georgia

Georgia law permits prescribers to issue Schedule IV prescriptions via telehealth after an audio-video evaluation. This is the fastest path for most patients.

The Georgia Composite Medical Board requires that a telehealth encounter for a controlled substance include a real-time, synchronous video visit. Asynchronous (store-and-forward) encounters alone do not satisfy the requirement for Schedule IV drugs. The prescriber must hold an active Georgia medical license or, for APRNs and PAs, a valid Georgia prescriptive authority registration. Under Georgia Code § 43-34-31.1, the standard of care for telehealth is identical to that of an in-person visit.

A typical telehealth visit for Dayvigo takes 15 to 25 minutes. The prescriber will review your sleep history, screen for obstructive sleep apnea, assess current medications for contraindications (particularly CYP3A4 inhibitors), and confirm that you have tried or considered cognitive behavioral therapy for insomnia (CBT-I). The American Academy of Sleep Medicine recommends CBT-I as first-line treatment for chronic insomnia per their 2021 clinical practice guideline [2].

After the visit, the prescriber sends an electronic prescription directly to a Georgia pharmacy. Georgia accepts e-prescriptions for Schedule IV substances. Most patients can pick up the medication within 24 to 72 hours, depending on pharmacy stock and insurance processing.

Who Can Prescribe Dayvigo in Georgia

Georgia allows multiple prescriber types to write for Schedule IV controlled substances. The distinctions matter if you are choosing a telehealth provider.

Medical doctors (MD) and doctors of osteopathy (DO) hold unrestricted prescriptive authority in Georgia and can prescribe Dayvigo without a collaborative agreement. Sleep medicine specialists and primary care physicians both prescribe it routinely.

Advanced practice registered nurses (APRNs) gained independent prescriptive authority in Georgia as of 2023 under the APRN Modernization Act, though protocol agreements with a physician are still required for the first 6,400 clinical hours. An APRN with full practice authority can prescribe Schedule III through V drugs, including lemborexant, without physician co-signature.

Physician assistants (PAs) prescribe under a delegated prescriptive authority agreement with a supervising physician. Georgia permits PAs to prescribe Schedule III through V drugs, so Dayvigo falls within scope. The supervising physician does not need to be physically present at the time of prescribing.

Psychologists and other non-prescribing providers cannot write the prescription but can refer you to a prescriber and coordinate care.

Insurance Coverage and Costs in Georgia

Coverage for Dayvigo varies sharply between commercial insurance, Medicare Part D, and Georgia Medicaid. Understanding your plan's formulary status before the visit saves time.

Commercial insurance: Most large commercial plans in Georgia (Blue Cross Blue Shield of Georgia, Anthem, Aetna, Cigna, UnitedHealthcare) place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A prior authorization is almost always required. The typical out-of-pocket cost after PA approval ranges from $30 to $60 per month for Tier 3 plans. Without insurance, a 30-day supply of Dayvigo 5 mg or 10 mg costs approximately $380 to $420 at retail pharmacies in Georgia.

Medicare Part D: Many Part D plans cover Dayvigo, but formulary placement varies by plan. Step therapy requiring a trial of a generic sleep aid (such as generic zolpidem or suvorexant) is common. The Medicare Part D formulary finder at medicare.gov lets you check your specific plan before committing to a visit.

Georgia Medicaid: Dayvigo is not covered under Georgia Medicaid for insomnia. Georgia Medicaid's preferred drug list does not include lemborexant for this indication. Patients on Medicaid should discuss alternatives such as generic suvorexant, doxepin 3 mg or 6 mg, or trazodone with their prescriber.

Eisai copay assistance: Eisai, the manufacturer of Dayvigo, offers a copay savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per fill for eligible patients. The card is not valid for government-funded insurance programs (Medicare, Medicaid, Tricare, VA). Patients can request the card directly from the Eisai patient support website or through their prescriber.

Prior Authorization Requirements in Georgia

Prior authorization is the single most common barrier to filling a Dayvigo prescription. Knowing what documentation your insurer needs helps your prescriber submit a clean PA on the first attempt.

Standard PA criteria across major Georgia insurers typically include: (1) a confirmed diagnosis of insomnia disorder (ICD-10 code G47.00 or G47.09), (2) documentation that the patient has tried and failed, or has a contraindication to, at least one generic sleep medication (zolpidem, eszopiclone, or suvorexant), (3) documentation that CBT-I was offered or attempted, and (4) confirmation that the patient does not have narcolepsy, severe hepatic impairment, or concomitant use of strong CYP3A4 inhibitors.

Your prescriber submits the PA electronically through the insurer's portal or by fax. Turnaround times in Georgia average 24 to 72 hours for standard requests. Urgent PAs may be processed in under 24 hours if the prescriber indicates clinical urgency. If the PA is denied, Georgia law requires the insurer to provide a written denial with appeal instructions. The appeal process typically involves the prescriber submitting additional clinical documentation, such as sleep diary data or polysomnography results.

A 2022 analysis in the American Journal of Managed Care found that prior authorization denials for branded insomnia medications were overturned on appeal approximately 40% to 60% of the time when the prescriber included objective sleep data [3].

Labs and Clinical Evaluation Before Starting Dayvigo

No routine blood work is required before starting lemborexant. This is one practical advantage over some other sleep medications.

The FDA label for Dayvigo does not mandate any pre-treatment laboratory testing. However, your prescriber may order labs based on your clinical picture. A comprehensive metabolic panel and thyroid function tests are sometimes checked to rule out medical causes of insomnia such as hyperthyroidism, hepatic disease, or renal impairment. Lemborexant is contraindicated in patients with severe hepatic impairment (Child-Pugh class C) because the drug is extensively metabolized by CYP3A4 and CYP3A5 in the liver [4].

If your prescriber suspects obstructive sleep apnea (OSA), a home sleep test or in-lab polysomnography may be ordered before prescribing any hypnotic. The SUNRISE-2 trial, a 12-month extension study (N=949), showed that lemborexant maintained efficacy over long-term use with a safety profile consistent with the initial 30-night trial [1]. Prescribers use this data to support ongoing prescriptions without mandatory repeat testing, though periodic reassessment of sleep symptoms is standard practice.

Weight, blood pressure, and a review of current medications (especially opioids, benzodiazepines, and CYP3A4 inhibitors like ketoconazole or clarithromycin) are documented at the initial visit. These do not require lab draws but do require accurate medication reconciliation.

Pharmacy Access and Filling in Georgia

Georgia has both chain and independent pharmacies stocking Dayvigo. The medication is a brand-only product with no generic available as of May 2026.

Chain pharmacies (CVS, Walgreens, Kroger, Publix, Walmart) in metro Atlanta and other Georgia cities stock Dayvigo or can order it within one to two business days. Rural pharmacies may need to special-order the drug, which can add one to three business days. Calling ahead to confirm stock is practical.

Mail-order pharmacies are an option for patients who prefer home delivery. Most commercial insurance plans allow 90-day mail-order fills, which often come with a lower per-unit copay. Express Scripts, OptumRx, and CVS Caremark all fill Dayvigo prescriptions by mail in Georgia.

503A compounding pharmacies in Georgia are licensed and operational, but compounding of lemborexant is not standard practice because the drug is commercially available in its FDA-approved form. Compounding pharmacies may only prepare a compounded version if the commercial product is on the FDA drug shortage list or if a patient has a documented medical need for an altered formulation (such as a liquid suspension for patients who cannot swallow tablets). As of this writing, lemborexant is not on the FDA drug shortage list.

Prescription transfers are permitted in Georgia for Schedule IV drugs. If you move to Georgia from another state or switch pharmacies within Georgia, your pharmacist can transfer the remaining refills. The receiving pharmacy contacts the originating pharmacy directly. Georgia Board of Pharmacy rules allow the transfer of Schedule III through V prescriptions one time between pharmacies.

Clinical Considerations Specific to Georgia Patients

Certain clinical factors are worth noting for Georgia residents considering Dayvigo.

Georgia ranks among the top 10 states for adult obesity prevalence at 33.9% according to CDC behavioral risk factor data [5]. Obesity is a major risk factor for obstructive sleep apnea, and insomnia frequently co-occurs with OSA. Prescribers in Georgia should screen for OSA before attributing sleep complaints solely to primary insomnia. The American Academy of Sleep Medicine's clinical guidelines note that DORA medications like lemborexant have not been studied extensively in patients with moderate-to-severe untreated OSA [2].

Dayvigo's safety profile is favorable for older adults. The SUNRISE-1 trial included patients aged 55 and older, and lemborexant 5 mg did not produce significantly more next-morning residual effects than placebo in this subgroup [1]. Georgia has 1.7 million residents aged 65 and older, making this a relevant consideration. The Beers Criteria from the American Geriatrics Society lists traditional benzodiazepine receptor agonists (zolpidem, eszopiclone) as potentially inappropriate in older adults due to fall risk, but DORAs like lemborexant and suvorexant are not on the current Beers list [6].

Alcohol interaction is a documented concern. The FDA label warns that lemborexant combined with alcohol increases CNS depression. Georgia's prescribers should counsel patients on this interaction, as alcohol use is prevalent across the state.

Step-by-Step Process to Get Dayvigo in Georgia

The process from initial consultation to first fill typically takes 3 to 10 days. Here is the sequence.

Step 1: Schedule a visit. Book a telehealth or in-person appointment with a licensed Georgia prescriber (MD, DO, APRN, or PA). Prepare a list of current medications, your sleep history, and any prior sleep medication trials.

Step 2: Clinical evaluation. The prescriber conducts a synchronous video or in-person assessment. Expect questions about sleep onset time, nighttime awakenings, daytime sleepiness, snoring, and alcohol or caffeine use.

Step 3: Prescription and PA submission. If Dayvigo is appropriate, the prescriber sends an e-prescription to your chosen Georgia pharmacy and, simultaneously, submits the prior authorization to your insurer with the required documentation.

Step 4: PA decision. Wait 24 to 72 hours for the PA decision. If denied, your prescriber can file a peer-to-peer review or formal appeal.

Step 5: Fill the prescription. Once approved, pick up Dayvigo at your pharmacy or arrange mail-order delivery. The standard starting dose is 5 mg taken once per night, no more than 30 minutes before bedtime, with at least 7 hours of remaining sleep time. Your prescriber may increase to 10 mg based on response and tolerability.

Patients paying cash without insurance should ask about the Eisai copay card or compare prices across pharmacies using pricing tools, as retail prices for Dayvigo in Georgia vary by $30 to $80 depending on the pharmacy.